cancer. 2009 oct 28. [epub ahead of print]

2
Cancer. 2009 Oct 28. [Epub ahead of print] Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Short LJ, Fisher MD, Wahl PM, Kelly MB, Lawless GD, White S, Rodriguez NA, Willey VJ, Brawley OW. HealthCore, Inc., Wilmington, Delaware. BACKGROUND:: African-American women have increased breast cancer mortality compared with white women. Diagnostic and treatment gaps may contribute to this disparity. METHODS:: In this retrospective, longitudinal cohort study, Southern US health plan claims data and linked medical charts were used to identify racial disparities in the diagnoses, treatment, and mortality of commercially insured women with newly diagnosed breast cancer. White women (n = 476) and African-American women (n = 99) with newly diagnosed breast cancer were identified by breast cancer claims codes (International Classification of Diseases, Ninth Revision, Clinical Modification codes 174, 233.0, 238.3, and 239.3) between January 2000 and December 2004. Race, diagnoses (breast cancer stage, estrogen/progesterone receptor [ER/PR]-positive status), treatment (breast-conserving surgery, antiestrogen therapy, and chemotherapy interruption or reduction), and all-cause mortality were assessed from medical charts. Multivariate regression analyses were adjusted for age, geography, and socioeconomic status to test the association of race with diagnoses/treatment. RESULTS:: White women were older (P < .001) and had higher rates of diagnosis at stage 0/I (55.2% vs 38.4%; P < .05) than African-American women. More white women had positive ER/PR status (75% vs 56% African-American; P = .001) and received antiestrogen therapy if they were positive (37.2% vs 27.3% African-American; P < .001). White women received slightly more breast-conserving surgery and chemotherapy dose modification than African-American women (P value nonsignificant). African- American women had a higher mortality rate (8.1%) than white women (3.6%; P = .06). In adjusted analyses, African-American women were diagnosed at later stages (odds ratio, 1.71; P = .02), and white women received more antiestrogen therapy (odds ratio, 2.1; P = .03). CONCLUSIONS:: Disparities in medical care among patients with newly diagnosed breast cancer were evident between African-American women and white women despite health plan insurance coverage. Interventions that address the gaps identified are needed. Cancer 2009. (c) 2009 American Cancer Society. PMID: 19877115 [PubMed - as supplied by publisher]

Upload: pepeaguilarjimenez

Post on 30-May-2018

220 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Cancer. 2009 Oct 28. [Epub Ahead of Print]

8/14/2019 Cancer. 2009 Oct 28. [Epub Ahead of Print]

http://slidepdf.com/reader/full/cancer-2009-oct-28-epub-ahead-of-print 1/1

Cancer. 2009 Oct 28. [Epub ahead of print]

Disparities in medical care among commercially insured patients withnewly diagnosed breast cancer: opportunities for intervention.

Short LJ , Fisher MD , Wahl PM , Kelly MB , Lawless GD , White S , Rodriguez NA ,Willey VJ , Brawley OW .

HealthCore, Inc., Wilmington, Delaware.

BACKGROUND:: African-American women have increased breast cancer mortalitycompared with white women. Diagnostic and treatment gaps may contribute to thisdisparity. METHODS:: In this retrospective, longitudinal cohort study, Southern UShealth plan claims data and linked medical charts were used to identify racial disparitiesin the diagnoses, treatment, and mortality of commercially insured women with newly

diagnosed breast cancer. White women (n = 476) and African-American women (n =99) with newly diagnosed breast cancer were identified by breast cancer claims codes(International Classification of Diseases, Ninth Revision, Clinical Modification codes174, 233.0, 238.3, and 239.3) between January 2000 and December 2004. Race,diagnoses (breast cancer stage, estrogen/progesterone receptor [ER/PR]-positive status),treatment (breast-conserving surgery, antiestrogen therapy, and chemotherapyinterruption or reduction), and all-cause mortality were assessed from medical charts.Multivariate regression analyses were adjusted for age, geography, and socioeconomicstatus to test the association of race with diagnoses/treatment. RESULTS:: Whitewomen were older (P < .001) and had higher rates of diagnosis at stage 0/I (55.2% vs38.4%; P < .05) than African-American women. More white women had positive

ER/PR status (75% vs 56% African-American; P = .001) and received antiestrogentherapy if they were positive (37.2% vs 27.3% African-American; P < .001). Whitewomen received slightly more breast-conserving surgery and chemotherapy dosemodification than African-American women (P value nonsignificant). African-American women had a higher mortality rate (8.1%) than white women (3.6%; P = .06).In adjusted analyses, African-American women were diagnosed at later stages (oddsratio, 1.71; P = .02), and white women received more antiestrogen therapy (odds ratio,2.1; P = .03). CONCLUSIONS:: Disparities in medical care among patients with newlydiagnosed breast cancer were evident between African-American women and whitewomen despite health plan insurance coverage. Interventions that address the gapsidentified are needed. Cancer 2009. (c) 2009 American Cancer Society.

PMID: 19877115 [PubMed - as supplied by publisher]